Grant of AESOP Options and PDMR Dealing

RNS Number : 6906G
Arecor Therapeutics PLC
17 November 2022
 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

Grant of AESOP Options, PDMR Dealing

 

Cambridge, UK,  17 November 2022:   Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives ,   announces that on 16 November 2022, it granted a total of 323,500 options under the Company's All Employee Share Ownership Plan ("AESOP Options") over new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares").

The AESOP Options vest after 36 months and are exercisable at £2.45 per share being the closing market price of an Ordinary Share on the day preceding the date of grant. The AESOP Options are subject to continuous employment, vest in accordance with the vesting term notified to the option holder and are exercisable until the tenth anniversary of the date of grant, after which date the option will lapse.

The following 159,000 AESOP Options were granted to persons discharging managerial responsibilities ("PDMR"):

PDMR

Position/status

Number of AESOP options granted on 16 November 2022

Total number of AESOP options held

Shafiq Choudhary

Managing Director, Tetris Pharma

40,000

40,000

David Gerring

VP Development

40,000

70,000

Sarah Howell

Chief Executive Officer

33,000

133,000

Jan Jezek

Chief Scientific Officer

13,000

53,000

Fiona Lawrence

VP Clinical Development and Reg. Affairs

10,000

40,000

Susan Lowther

Chief Financial Officer

23,000

93,000

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.  

For further information, please contact:

 

Arecor Therapeutics plc

 

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email:  info@arecor.com

 



Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email:  info@arecor.com

 

 


Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email:  mo.noonan@arecor.com



 

Panmure Gordon (UK) Limited

(NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

 

Tel: +44 (0) 20 7886 2500

 



 

Consilium Strategic Communications


Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email:  arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market   through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform,   Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat   ™ platform is supported by an extensive patent portfolio. 

 

For further details please see our website,  www.arecor.com

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Shafiq Choudhary

2. 

Reason for the notification

a)

Position/status:

Managing Director, Tetris Pharma

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

40,000

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

40,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue

 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

David Gerring

2. 

Reason for the notification

a)

Position/status:

VP Development

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

40,000

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

40,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue



 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Sarah Howell

2. 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

33,000

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

33,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue

 



 

 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Jan Jezek

2. 

Reason for the notification

a)

Position/status:

Chief Scientific Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

13,000

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

13,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue



 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Fiona Lawrence

2. 

Reason for the notification

a)

Position/status:

VP Clinical Development and Reg. Affairs

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

10,000

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

10,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue



 


Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Susan Lowther

2. 

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

  Exercise Price(s)

Volume(s)

£2.45

23,000

 

 

d)

Aggregated information:

·   Aggregated volume:

·   Price:

 

23,000

N/A

e)

Date of the transaction:

16 November 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANFKFDKAFFA
UK 100

Latest directors dealings